TrialThe Journal of clinical investigation2014

Targeting miR-23a in CD8+ cytotoxic T lymphocytes prevents tumor-dependent immunosuppression.

Regina Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.